Scarica l'app Stockscreener
2.00
31.97%
-0.94
Dopo l'orario di chiusura:
2.01
0.010
+0.50%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.94
Aprire:
$2.07
Volume 24 ore:
11.18M
Relative Volume:
11.01
Capitalizzazione di mercato:
$134.72M
Reddito:
$488.00K
Utile/perdita netta:
$-41.44M
Rapporto P/E:
-2.1505
EPS:
-0.93
Flusso di cassa netto:
$-31.47M
1 W Prestazione:
-28.83%
1M Prestazione:
-36.91%
6M Prestazione:
-49.62%
1 anno Prestazione:
-41.35%
Intervallo 1D:
$1.85
$2.10
Intervallo di 1 settimana:
$1.85
$3.05
Portata 52W:
$1.85
$4.99
Cardiff Oncology Inc Stock (CRDF) Company Profile
Nome
Cardiff Oncology Inc
Settore
Industria
Telefono
858-952-7570
Indirizzo
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Confronta CRDF con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
2.00 | 198.04M | 488.00K | -41.44M | -31.47M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-05 | Iniziato | Noble Capital Markets | Outperform |
| 2025-07-08 | Iniziato | Ladenburg Thalmann | Buy |
| 2025-06-24 | Iniziato | Jefferies | Hold |
| 2024-09-06 | Iniziato | Craig Hallum | Buy |
| 2022-01-05 | Iniziato | William Blair | Outperform |
| 2021-12-08 | Iniziato | Robert W. Baird | Outperform |
| 2021-08-09 | Ripresa | Maxim Group | Buy |
| 2020-10-22 | Iniziato | H.C. Wainwright | Buy |
| 2020-10-08 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Cardiff Oncology Inc Borsa (CRDF) Ultime notizie
Cardiff To Pursue Narrower CRC Market For Onvansertib As Top Execs Step Down - Citeline News & Insights
Cardiff Oncology Overhauls Leadership to Advance Onvansertib - TipRanks
Favorite son in PLK1? Cardiff dips as phase II CRC bid advances - BioWorld MedTech
CEO transition at Cardiff Oncology (NASDAQ: CRDF) paired with positive Phase 2 trial - Stock Titan
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Cardiff Oncology (CRDF) Shares Plunge After Executive Departures and Trial Update - GuruFocus
Cardiff Oncology Shares Plunge 35% Following CEO and CFO Resignations - Intellectia AI
Cardiff Oncology Sees Unusually Large Options Volume (NASDAQ:CRDF) - MarketBeat
Cardiff Oncology Taps Interim CEO, Picks 30mg Onvansertib Regimen for 2026 Registrational mCRC Study - Yahoo Finance
Cardiff Oncology down after leadership shakeup (CRDF:NASDAQ) - Seeking Alpha
Cardiff Oncology stock tumbles after Phase 2 trial data update By Investing.com - Investing.com Canada
Cardiff Oncology appoints interim CEO amid leadership transition By Investing.com - Investing.com Canada
Cardiff Oncology plunges after top executives step down - TradingView
Cardiff Oncology (CRDF) Reports Promising Phase 2 Trial Results - GuruFocus
Cardiff Oncology appoints interim CEO amid leadership transition - Investing.com
Cardiff Oncology (CRDF) Announces Leadership Changes - GuruFocus
Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC - The Manila Times
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development - manilatimes.net
Cardiff Oncology reports positive phase 2 data for cancer drug By Investing.com - Investing.com UK
Cardiff Oncology Announces Positive Update from its - GlobeNewswire
Cancer biotech Cardiff Oncology swaps leaders as key drug nears late-stage tests - Stock Titan
Guidance Update: Can SPAR Group Inc generate free cash flowJuly 2025 Pullbacks & Real-Time Market Sentiment Reports - baoquankhu1.vn
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update - ADVFN
CRDFTrovagene Presents Outlook for Second Half of 2018 - ADVFN
3 Promising Penny Stocks With Market Caps Below $600M - simplywall.st
How Cardiff Oncology Inc. stock benefits from tech adoptionMorning Star Patterns & Free Long-Term Investment Planning - bollywoodhelpline.com
Gains Recap: Should you buy the dip on Cardiff Oncology Inc2025 Bull vs Bear & Weekly High Return Forecasts - baoquankhu1.vn
Will Cardiff Oncology Inc. benefit from sector rotationJuly 2025 Snapshot & Safe Entry Trade Reports - bollywoodhelpline.com
What hedge fund moves indicate for Cardiff Oncology Inc. (XE7C) stock2025 Sector Review & Weekly Setup with ROI Potential - bollywoodhelpline.com
Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives $11.13 Consensus Price Target from Brokerages - Defense World
Cardiff Oncology: What Storms Can We Expect In 2026? The Case For Measured Enthusiasm (NASDAQ:CRDF) - Seeking Alpha
Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Is Cardiff Oncology Inc. stock a buy for dividend growthJuly 2025 Action & Long Hold Capital Preservation Tips - Улправда
Aug Wrap: How Cardiff Oncology Inc XE7C stock reacts to Fed tightening2025 Breakouts & Breakdowns & Fast Gain Stock Tips - Bộ Nội Vụ
How Cardiff Oncology Inc. (XE7C) stock reacts to Fed tighteningRisk Management & Stepwise Swing Trade Plans - Улправда
Equities Analysts Issue Forecasts for CRDF Q4 Earnings - Defense World
Can Cardiff Oncology Inc. stock double in next 5 yearsDividend Growth Stocks & Today’s Picks, Tomorrow’s Winners - ulpravda.ru
Q4 Earnings Estimate for CRDF Issued By Noble Financial - MarketBeat
What is Noble Financial’s Estimate for CRDF FY2025 Earnings? - Defense World
Analysts Offer Predictions for CRDF FY2025 Earnings - MarketBeat
Cardiff Oncology stock initiated with Outperform rating by Noble Capital - Investing.com Australia
Noble Financial Initiates Coverage on Cardiff Oncology (NASDAQ:CRDF) - MarketBeat
Cardiff Oncology Inc. (CRDF) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Investors Purchase High Volume of Call Options on Cardiff Oncology (NASDAQ:CRDF) - Defense World
Cardiff Oncology (FRA:XE7C) EV-to-OCF : -3.04 (As of Dec. 24, 2025) - GuruFocus
Stock Traders Purchase High Volume of Cardiff Oncology Call Options (NASDAQ:CRDF) - MarketBeat
Flputnam Investment Management Co. Purchases 543,370 Shares of Cardiff Oncology, Inc. $CRDF - MarketBeat
Why analysts raise outlook for Cardiff Oncology Inc. (XE7C) stockTrade Analysis Report & Precise Swing Trade Entry Alerts - Улправда
3 Penny Stocks With At Least $100M Market Cap - simplywall.st
Short Covering: How analysts revise price targets for ConAgra Brands Inc stockPrice Action & Low Risk Profit Maximizing Plans - moha.gov.vn
Cardiff Oncology Earnings Notes - Trefis
Cardiff Oncology Inc Azioni (CRDF) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.09%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):